FDA Issues Updated Final eCopy Submission Guidance

The FDA issued an updated final guidance document titled “eCopy Program for Medical Device Submissions” on December 3, 2025. This guidance replaces the 2020 version and reinforces the importance of proper formatting to prevent submission delays or potential closure. It also clarifies how the eCopy program aligns with the new eSTAR program and introduces minor technical updates, significantly impacting how medical device manufacturers prepare and submit documentation through the online CDRH Portal.

Key Updates from the FDA eCopy Submission Guidance

Integration with eSTAR and the CDRH Portal:
Clarifies that the eSTAR program is the current standard for submissions. The eCopy program applies to submissions that have not yet transitioned to eSTAR. Both submission formats can now be submitted through the CDRH Customer Collaboration Portal.

• Modernized Technical Standards:
  The guidance includes minor updates to reflect current technology.

• Consequences of Non-Compliance:
  The guidance emphasizes that submissions with an invalid eCopy format will be placed on a “Format Hold.”

• Recommended Tools:
  The FDA strongly recommends using its free, optional tools to help ensure compliance.

Impact on Manufacturers 

The primary impact for manufacturers is the need for strict adherence to specified electronic formats to avoid submission delays, along with the ongoing transition toward the fully electronic eSTAR system.

• Mandatory Electronic Submissions:
  Specific submission types—such as all 510(k)s (since October 1, 2023) and De Novo requests (beginning October 1, 2025)—must now be submitted using the FDA’s Electronic Submission Template and Resource (eSTAR). The eCopy program is largely reserved for submission types that have not yet transitioned to eSTAR.

• “Format Holds” and Review Delays:
  Submissions that do not meet the precise technical standards of either the eCopy or eSTAR programs will be placed on a “Format Hold,” and the FDA’s review clock will not begin.

• Submission Withdrawal:
  Manufacturers have 180 days to correct a submission placed on format hold; otherwise, it will be considered withdrawn and closed.

• Updated Technical Standards:
  The guidance provides updated technical standards and clarifications, including:
  • File Size: Recommended total eCopy size is less than 4 GB.
  • File Naming: PDF files must begin with a three-digit prefix (e.g., “001_”) to ensure the correct loading order.
  • File Content: PDFs must be searchable, not password-protected, and must not contain special characters in file names.
  • Submission Method: Submissions may be submitted online through the CDRH Portal (for CDRH submissions) or via physical media (CD, DVD, or flash drive) for other submission types.

• The FDA recommends using its optional tools:
  • The eSubmitter-eCopies Tool helps ensure proper formatting during submission creation.
  • The eCopy Validation Module allows manufacturers to check final eCopy submissions for common errors before submitting them to the agency.

This updated guidance is critical for medical device manufacturers to ensure submissions are properly formatted and aligned with the FDA’s digital requirements, enabling a smoother, more efficient review process and helping to avoid unnecessary delays.

How MedEnvoy Can Support 

Navigating the FDA’s evolving submission requirements can be complex, especially with the transition from eCopy to eSTAR and the technical standards that must be met to avoid costly delays. MedEnvoy offers comprehensive support to ensure your submissions are compliant and timely: 

• Submission Formatting Expertise: We help manufacturers prepare eCopy and eSTAR submissions that meet FDA’s precise technical requirements, including file naming, size limits, and searchable content. 

• Validation and Pre-Check Services: Using FDA-recommended tools and our internal quality checks, we validate your submission before it reaches the agency, reducing the risk of “Format Holds.” 

• Strategic Guidance on Transition to eSTAR: Our team provides tailored advice for manufacturers moving from eCopy to eSTAR, ensuring a smooth transition aligned with FDA timelines. 

• End-to-End Regulatory Support: From initial planning to final submission, MedEnvoy acts as your regulatory partner, helping you avoid delays and maintain compliance throughout the process. 

Partnering with MedEnvoy means peace of mind and that your submissions will be accurate, compliant, and ready for FDA review without unnecessary setbacks. 

If you have any questions regarding this summary or the accompanying guidance document, we encourage you to contact our team for tailored support.